{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:46:42Z","timestamp":1785548802414,"version":"3.56.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.ijantimicag.2015.12.021","type":"journal-article","created":{"date-parts":[[2016,2,21]],"date-time":"2016-02-21T13:45:15Z","timestamp":1456062315000},"page":"250-258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance"],"prefix":"10.1016","volume":"47","author":[{"given":"Ling-Shan","family":"Syue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Hsu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chien","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7502-9225","authenticated-orcid":false,"given":"Po-Ren","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0475","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1086\/378702","article-title":"Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections","volume":"37","author":"Solomkin","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0480","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1001\/archsurg.1993.01420140070011","article-title":"Surgical Infection Society intra-abdominal infection study: prospective evaluation of management techniques and outcome","volume":"128","author":"Christou","year":"1993","journal-title":"Arch Surg"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0485","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1086\/649554","article-title":"Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America","volume":"50","author":"Solomkin","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0490","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1749-7922-8-3","article-title":"WSES guidelines for management of intra-abdominal infections","volume":"8","author":"Sartelli","year":"2013","journal-title":"World J Emerg Surg"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0495","doi-asserted-by":"crossref","first-page":"e0119956","DOI":"10.1371\/journal.pone.0119956","article-title":"Clinical and economic consequences of failure of initial antibiotic therapy for patients with community-onset complicated intra-abdominal infections","volume":"10","author":"Chong","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0500","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1749-7922-9-37","article-title":"Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study","volume":"9","author":"Sartelli","year":"2014","journal-title":"World J Emerg Surg"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0505","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1749-7922-7-36","article-title":"Complicated intra-abdominal infections in Europe: a comprehensive review of the CIAO study","volume":"7","author":"Sartelli","year":"2012","journal-title":"World J Emerg Surg"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0510","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/jac\/dki117","article-title":"In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART)","volume":"55","author":"Paterson","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0515","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ijantimicag.2009.07.013","article-title":"In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005\u20132007: results from the SMART study","volume":"34","author":"Hawser","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0520","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jmii.2013.07.002","volume":"48","author":"Jean","year":"2015","journal-title":"J Microbiol Immunol Infect"},{"issue":"Suppl.","key":"10.1016\/j.ijantimicag.2015.12.021_bib0525","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0924-8579(12)70003-1","article-title":"Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002\u20132010","volume":"40","author":"Huang","year":"2012","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl.","key":"10.1016\/j.ijantimicag.2015.12.021_bib0530","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0924-8579(12)00244-0","article-title":"Study for Monitoring Antimicrobial Resistance Trends (SMART) in the Asia-Pacific region, 2002\u20132010","volume":"40","author":"Hsuech","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0535","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1128\/AAC.00971-12","volume":"57","author":"Sheng","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0540","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.diagmicrobio.2015.03.025","article-title":"Characterization of extended-spectrum \u03b2-lactamases and antimicrobial resistance of Klebsiella pneumoniae in intra-abdominal infection isolates in Latin America, 2008\u20132012. Results of the Study for Monitoring Antimicrobial Resistance Trends","volume":"82","author":"Kazmierczak","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0545","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/jac\/dkr081","article-title":"Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007\u201309)","volume":"66","author":"Castanheira","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0550","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jmii.2014.02.004","article-title":"Correlation between antibiotic consumption and carbapenem-resistant Acinetobacter baumannii causing health care-associated infections at a hospital from 2005 to 2010","volume":"48","author":"Tan","year":"2015","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0555","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijid.2015.04.011","article-title":"Susceptibility trends and molecular characterization of Gram-negative bacilli associated with urinary tract and intra-abdominal infections in Jordan and Lebanon: SMART 2011\u20132013","volume":"35","author":"Hayajneh","year":"2015","journal-title":"Int J Infect Dis"},{"issue":"Suppl.","key":"10.1016\/j.ijantimicag.2015.12.021_bib0560","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0924-8579(12)70007-9","volume":"40","author":"Lee","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0565","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jinf.2013.09.001","article-title":"Susceptibility of Gram-negative aerobic bacilli from intra-abdominal pathogens to antimicrobial agents collected in the United States during 2011","volume":"68","author":"Hawser","year":"2014","journal-title":"J Infect"},{"issue":"Suppl.","key":"10.1016\/j.ijantimicag.2015.12.021_bib0570","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0924-8579(12)70004-3","article-title":"In vitro susceptibilities of non-Enterobacteriaceae isolates from patients with intra-abdominal infections in the Asia-Pacific region from 2003 to 2010: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART)","volume":"40","author":"Liu","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0575","series-title":"22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) Annual Meeting","article-title":"Susceptibility of intra-abdominal pathogens in Europe, Africa and Middle East\u2014SMART 2010\/2011","author":"Badal","year":"2012"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0580","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ijantimicag.2012.10.014","article-title":"Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002\u20132010","volume":"41","author":"Hawser","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0585","series-title":"52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"Global susceptibility and ESBL+ rates of K. pneumoniae from intra-abdominal infections\u2014SMART 2011","author":"Badal","year":"2012"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0590","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/sur.2007.041","article-title":"Choosing antibiotics for intra-abdominal infections: what do we mean by \u2018high risk\u2019?","volume":"10","author":"Swenson","year":"2009","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0595","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.diagmicrobio.2006.08.016","article-title":"Comparative activities of cefepime and piperacillin\/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype","volume":"57","author":"Sader","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0600","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1016\/j.bmcl.2008.07.085","article-title":"Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205","volume":"18","author":"Toda","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0605","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","article-title":"Ceftolozane\/tazobactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli","volume":"74","author":"Zhanel","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0610","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1128\/AAC.02253-13","article-title":"Activity of ceftolozane\u2013tazobactam against a broad spectrum of recent clinical anaerobic isolates","volume":"58","author":"Snydman","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0615","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/jac\/dkq248","article-title":"Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus \u03b2-lactamase-producing Enterobacteriaceae","volume":"65","author":"Livermore","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0620","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1128\/AAC.00049-14","article-title":"Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane\u2013tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections","volume":"58","author":"Lucasti","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0625","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0630","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.mib.2011.07.026","article-title":"Diazabicyclooctanes (DBOs): a potent new class of non-\u03b2-lactam \u03b2-lactamase inhibitors","volume":"14","author":"Coleman","year":"2011","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0635","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime\u2013avibactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0640","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1128\/AAC.04218-14","article-title":"In vitro antibacterial activity of the ceftazidime\u2013avibactam combination against Enterobacteriaceae, including strains with well-characterized \u03b2-lactamases","volume":"59","author":"Levasseur","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0645","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1128\/AAC.06064-11","article-title":"In vitro antibacterial activity of the ceftazidime\u2013avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates","volume":"56","author":"Levasseur","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0650","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1128\/AAC.01682-10","article-title":"In vitro activity of ceftazidime\u2013NXL104 against 396 strains of \u03b2-lactamase-producing anaerobes","volume":"55","author":"Citron","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0655","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1128\/AAC.02429-13","article-title":"Antimicrobial activity of ceftazidime\u2013avibactam against Gram-negative organisms collected from U.S. medical centers in 2012","volume":"58","author":"Sader","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0660","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1128\/AAC.00548-15","article-title":"Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum \u03b2-lactamases and porin mutations on the in vitro activity of ceftazidime\u2013avibactam against carbapenem-resistant Klebsiella pneumoniae","volume":"59","author":"Shields","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0665","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0670","unstructured":"Forest Pharmaceuticals Inc. Avycaz highlights of prescribing information. Cincinnati, OH: Forest Pharmaceuticals Inc. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206494s000lbl.pdf [accessed 19.01.16]."},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0675","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijantimicag.2015.02.027","article-title":"Ecological effect of ceftazidime\/avibactam on the normal human intestinal microbiota","volume":"46","author":"Rashid","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0680","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1093\/jac\/dkv132","article-title":"Pharmacokinetics\/pharmacodynamics of a \u03b2-lactam and \u03b2-lactamase inhibitor combination: a novel approach for aztreonam\/avibactam","volume":"70","author":"Singh","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0685","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1128\/AAC.00206-15","article-title":"In vitro activity of aztreonam\u2013avibactam against a global collection of Gram-negative pathogens from 2012 and 2013","volume":"59","author":"Biedenbach","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0690","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jmii.2013.09.001","article-title":"Nationwide spread of Klebsiella pneumoniae carbapenemase-2-producing K. pneumoniae sequence type 11 in Taiwan","volume":"46","author":"Jean","year":"2013","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0695","unstructured":"ClnicalTrials.gov. To investigate the safety and tolerability of aztreonam\u2013avibactam (ATM-AVI). Identifier NCT01689207. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01689207?term=aztreonam+avibactam&rank=1 [accessed 19.01.16]."},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0700","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1177\/1060028014556652","article-title":"\u03b2-Lactam\/\u03b2-lactamase inhibitor combinations: from then to now","volume":"49","author":"Toussaint","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0705","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1128\/AAC.00830-15","article-title":"Activity of imipenem with relebactam against Gram-negative pathogens from New York City","volume":"59","author":"Lapuebla","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0710","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1128\/AAC.05927-11","article-title":"In vitro activity of MK-7655, a novel \u03b2-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria","volume":"56","author":"Hirsch","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0715","unstructured":"ClinicalTrials.gov. Study of the safety, tolerability, and efficacy of MK-7655+ imipenem\/cilastatin versus imipenem\/cilastatin alone to treat complicated intra-abdominal infection [cIAI] (MK-7655-004). Identifier NCT01506271. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01506271?term=MK-7655&rank=1 [accessed 19.01.16]."},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0720","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","article-title":"Discovery of a cyclic boronic acid \u03b2-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases","volume":"58","author":"Hecker","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0725","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1128\/AAC.00843-15","article-title":"Activity of meropenem combined with RPX7009, a novel \u03b2-lactamase inhibitor, against Gram-negative clinical isolates in New York City","volume":"59","author":"Lapuebla","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0730","unstructured":"ClinicalTrials.gov. Efficacy, safety, tolerability of Carbavance compared to best available therapy in serious infections due to carbapenem resistant Enterobacteriaceae, in adults. Identifier: NCT02168946. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02168946 [accessed 19.01.16]."},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0735","series-title":"25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)","article-title":"S-649266, a novel siderophore cephalosporin: binding affinity to PBP and bactericidal activity","author":"Ito","year":"2015"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0740","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10534-009-9219-2","article-title":"Siderophores as drug delivery agents: application of the \u2018Trojan Horse\u2019 strategy","volume":"22","author":"M\u00f6llmann","year":"2009","journal-title":"Biometals"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0745","article-title":"In vitro antimicrobial activity of siderophore cephalosporin S-649266 against Enterobacteriaceae clinical isolates including carbapenem-resistant strains","author":"Kohira","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2015.12.021_bib0750","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1093\/ofid\/ofu052.118","article-title":"S-649266, a novel siderophore cephalosporin: in vitro activity against Gram-negative bacteria","volume":"1","author":"Tsuji","year":"2014","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0755","unstructured":"ClinicalTrials.gov. Efficacy and safety of intravenous S-649266 versus intravenous imipenem\/cilastatin in complicated urinary tract infections with or without pyelonephritis or acute uncomplicated pyelonephritis caused by Gram-negative pathogens in hospitalized adults. Identifier: NCT02321800. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02321800?term=S649266&rank=1 [accessed 19.01.16]."},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0760","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ijantimicag.2014.02.017","article-title":"In vitro activity of the siderophore monosulfactam BAL30072 against contemporary Gram-negative pathogens from New York City, including multidrug-resistant isolates","volume":"43","author":"Landman","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0765","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijantimicag.2013.05.010","article-title":"In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens","volume":"42","author":"Hornsey","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0770","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1021\/jm201465w","article-title":"Fluorocyclines 1,7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent","volume":"55","author":"Xiao","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0775","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1021\/jm201467r","article-title":"Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy","volume":"55","author":"Clark","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0780","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1128\/AAC.01288-13","article-title":"Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens","volume":"57","author":"Sutcliffe","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0785","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.01614-13","article-title":"Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections","volume":"58","author":"Solomkin","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0790","unstructured":"ClinicalTrials.gov. Efficacy and safety study of eravacycline compared with ertapenem in complicated intra-abdominal infections. Identifier: NCT01844856. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01844856?term=eravacycline&rank=1 [accessed 19.01.16]."},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0795","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1517\/13543784.2014.965253","article-title":"Eravacycline for the treatment of intra-abdominal infections","volume":"23","author":"Bassetti","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0800","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1586\/eri.12.25","article-title":"Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin","volume":"10","author":"Zhanel","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0805","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1179\/1973947812Y.0000000015","article-title":"Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece","volume":"24","author":"Galani","year":"2012","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0810","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/jac\/dkq408","article-title":"Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates","volume":"66","author":"Livermore","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0815","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.1128\/AAC.00624-11","article-title":"Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects","volume":"55","author":"Cass","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0820","unstructured":"ClinicalTrials.gov. A study of plazomicin compared with colistin in patients with infection due to carbapenem-resistant Enterobacteriaceae (CRE) (CARE). Identifier: NCT01970371. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01970371?term=Plazomicin&rank=1 [accessed 19.01.16]."},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0825","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1128\/AAC.47.10.3260-3269.2003","article-title":"In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone","volume":"47","author":"Nilius","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0830","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/jac\/dkh180","article-title":"Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492","volume":"53","author":"Harnett","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0835","unstructured":"ClinicalTrials.gov. Delafloxacin versus vancomycin and aztreonam for the treatment of acute bacterial skin and skin structure infections. Identifier: NCT01984684. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01984684 [accessed 19.01.16]."},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0840","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ijantimicag.2014.07.006","article-title":"Activity of the investigational fluoroquinolone finafloxacin and seven other antimicrobial agents against 114 obligately anaerobic bacteria","volume":"44","author":"Genzel","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0845","unstructured":"ClinicalTrials.gov. Finafloxacin 300mg twice a day (b.i.d.) versus ciprofloxacin 250mg twice a day (b.i.d) in patients with lower uncomplicated UTI (uUTI) (FLUT). Identifier: NCT00722735. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00722735 [accessed 19.01.16]."},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0850","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1086\/648438","article-title":"Telavancin: a novel lipoglycopeptide","volume":"49","author":"Saravolatz","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0855","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/526772","article-title":"Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic","volume":"46","author":"Billeter","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0860","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1592\/phco.30.1.80","article-title":"A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin","volume":"30","author":"Guskey","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0865","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","article-title":"New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin","volume":"70","author":"Zhanel","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0870","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/jac\/dkp286","article-title":"Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin","volume":"64","author":"Arhin","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0875","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1128\/AAC.06067-11","article-title":"Oritavancin activity against vancomycin-susceptible and vancomycin-resistant enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009\u20132010","volume":"56","author":"Mendes","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0880","series-title":"48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)\/46th Infectious Diseases Society of America (IDSA) Annual Meeting","article-title":"Hematological effects of TR-701, linezolid and placebo administered for 21 days in healthy subjects","author":"Prokocimer","year":"2008"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0885","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/cid\/civ501","article-title":"Tedizolid: the first once-daily oxazolidinone class antibiotic","volume":"61","author":"Steven","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0890","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial","volume":"309","author":"Prokocimer","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0895","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","article-title":"Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin structure infections (ESTABLISH-2): a randomized, double-blind, phase 3, non-inferiority trial","volume":"14","author":"Moran","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0900","unstructured":"ClinicalTrials.gov. TR-701 FA vs linezolid for the treatment of nosocomial pneumonia. Identifier: NCT0201940. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02019420?term=TR701&rank=3 [accessed 19.01.16]."},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0905","unstructured":"ClinicalTrials.gov. Safety and efficacy study of oxazolidinone to treat pneumonia. Identifier: NCT00640926. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00640926?term=oxazolidinone&rank=1 [accessed 19.01.16]."},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0910","unstructured":"ClinicalTrials.gov. Safety and efficacy study of oxazolidinones to treat uncomplicated skin infections. Identifier: NCT00646958. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00646958?term=oxazolidinone&rank=2 [accessed 19.01.16]."},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0915","series-title":"WHO's first global report on antibiotic resistance reveals serious, worldwide threat to public health","author":"World Health Organization","year":"2014"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0920","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2014.01.006","article-title":"Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections","volume":"44","author":"Falagas","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0925","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jmii.2013.11.005","article-title":"In vitro activity of colistin sulfate against Enterobacteriaceae producing extended-spectrum \u03b2-lactamases","volume":"48","author":"Ku","year":"2015","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0930","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/cid\/cis588","article-title":"Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy","volume":"55","author":"Tumbarello","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0935","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jmii.2013.05.007","article-title":"Synergy of imipenem\/colistin methanesulfonate combinations against imipenem-nonsusceptible multidrug-resistant Acinetobacter baumannii","volume":"47","author":"Leu","year":"2014","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2015.12.021_bib0940","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1056\/NEJMoa1411162","article-title":"Trial of short-course antimicrobial therapy for intraabdominal infection","volume":"372","author":"Sawyer","year":"2015","journal-title":"N Engl J Med"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857916000455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857916000455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T20:54:35Z","timestamp":1536958475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857916000455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":94,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0924857916000455"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.12.021","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}